• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:15:48 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TKNO alert in real time by email
    8-K
    false000185090200018509022025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    Alpha Teknova, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40538

    94-3368109

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2451 Bert Drive

     

    Hollister, California

     

    95023

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 831 637-1100

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

     

    TKNO

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, the Company issued a press release announcing its financial results for the first quarter ended March 31, 2025 (the “Press Release”). A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the Press Release, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    99.1

    Press Release issued by Alpha Teknova, Inc., dated May 8, 2025.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    *

    Non-material schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ALPHA TEKNOVA, INC.

     

     

     

     

    Date:

    May 8, 2025

    By:

    /s/ Stephen Gunstream

     

     

     

    Stephen Gunstream
    President and Chief Executive Officer

     


    Get the next $TKNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TKNO

    DatePrice TargetRatingAnalyst
    7/22/2025$8.00Overweight
    Stephens
    2/10/2025$12.00Buy
    Craig Hallum
    3/12/2024Buy → Neutral
    BTIG Research
    7/20/2021Overweight
    Stephens
    7/20/2021$27.00Overweight
    Stephens & Co.
    7/20/2021Outperform
    Cowen & Co.
    7/20/2021$26.00Buy
    BTIG
    More analyst ratings

    $TKNO
    SEC Filings

    View All

    SEC Form 10-Q filed by Alpha Teknova Inc.

    10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

    8/8/25 4:07:19 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alpha Teknova, Inc. (0001850902) (Filer)

    8/7/25 4:07:41 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Alpha Teknova Inc.

    EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)

    7/17/25 12:15:12 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Demski Martha J sold $40,512 worth of shares (8,000 units at $5.06), decreasing direct ownership by 40% to 12,000 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:59:45 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Vos Alexander

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Robertson Brett

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:06 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 9:13:16 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:04 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Alpha Teknova with a new price target

    Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

    7/22/25 7:51:11 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Craig Hallum initiated coverage on Alpha Teknova with a new price target

    Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

    2/10/25 8:24:48 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova downgraded by BTIG Research

    BTIG Research downgraded Alpha Teknova from Buy to Neutral

    3/12/24 7:34:27 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Leadership Updates

    Live Leadership Updates

    View All

    Teknova Announces New Board Member, Martha J. Demski

    HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

    8/16/23 8:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Financials

    Live finance-specific insights

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alpha Teknova Inc.

    SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    10/6/23 4:10:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care